Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-10-10

Clinical Trial Update: Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for CJM112 in moderate to severe inflammatory acne completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CJM112

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acne Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2019-10-10